
Michael H. Caley
Supervisory Patent Examiner (ID: 3988, Phone: (571)272-2286 , Office: P/2871 )
| Most Active Art Unit | 2871 |
| Art Unit(s) | 2882, 2871 |
| Total Applications | 862 |
| Issued Applications | 596 |
| Pending Applications | 34 |
| Abandoned Applications | 236 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17228564
[patent_doc_number] => 20210355120
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => BENZOQUINOLONE INHIBITORS OF VMAT2
[patent_app_type] => utility
[patent_app_number] => 17/219176
[patent_app_country] => US
[patent_app_date] => 2021-03-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13489
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 39
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17219176
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/219176 | BENZOQUINOLONE INHIBITORS OF VMAT2 | Mar 30, 2021 | Abandoned |
Array
(
[id] => 17124382
[patent_doc_number] => 20210299150
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => AP39 IMPACT ON MITOCHONDRIA, METABOLISM, GENE TRANSCRIPTION REGULATION, CARDIOTOXICITY PROTECTION AND CANCER TREATMENT
[patent_app_type] => utility
[patent_app_number] => 17/217462
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17036
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217462
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/217462 | AP39 IMPACT ON MITOCHONDRIA, METABOLISM, GENE TRANSCRIPTION REGULATION, CARDIOTOXICITY PROTECTION AND CANCER TREATMENT | Mar 29, 2021 | Abandoned |
Array
(
[id] => 18127926
[patent_doc_number] => 11554121
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-17
[patent_title] => Compositions and methods for inhibiting type 1 collagen production
[patent_app_type] => utility
[patent_app_number] => 17/217091
[patent_app_country] => US
[patent_app_date] => 2021-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 18
[patent_no_of_words] => 5390
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17217091
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/217091 | Compositions and methods for inhibiting type 1 collagen production | Mar 29, 2021 | Issued |
Array
(
[id] => 19232066
[patent_doc_number] => 20240189257
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-13
[patent_title] => COMPOSITIONS AND METHODS FOR MANAGING NEPHROPATHY
[patent_app_type] => utility
[patent_app_number] => 18/282672
[patent_app_country] => US
[patent_app_date] => 2021-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7093
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18282672
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/282672 | COMPOSITIONS AND METHODS FOR MANAGING NEPHROPATHY | Mar 24, 2021 | Pending |
Array
(
[id] => 18359764
[patent_doc_number] => 20230141355
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19
[patent_app_type] => utility
[patent_app_number] => 17/914529
[patent_app_country] => US
[patent_app_date] => 2021-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17914529
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/914529 | CXCL8 INHIBITORS FOR USE IN THE TREATMENT OF COVID-19 | Mar 23, 2021 | Pending |
Array
(
[id] => 18418430
[patent_doc_number] => 20230172888
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-08
[patent_title] => COMPOSITIONS AND METHODS FOR THE TREATMENT OF THREATENED RESPIRATORY FAILURE CAUSED BY CORONAVIRUS INFECTION AND DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/912711
[patent_app_country] => US
[patent_app_date] => 2021-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11194
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17912711
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/912711 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF THREATENED RESPIRATORY FAILURE CAUSED BY CORONAVIRUS INFECTION AND DISEASE | Mar 17, 2021 | Pending |
Array
(
[id] => 16976128
[patent_doc_number] => 20210220365
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-22
[patent_title] => TREATMENT OF AUTISM SPECTRUM DISORDERS, OBSESSIVE-COMPULSIVE DISORDER AND ANXIETY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/204648
[patent_app_country] => US
[patent_app_date] => 2021-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 68450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17204648
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/204648 | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders | Mar 16, 2021 | Issued |
Array
(
[id] => 19535501
[patent_doc_number] => 12128034
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-29
[patent_title] => Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/198335
[patent_app_country] => US
[patent_app_date] => 2021-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 23781
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198335
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/198335 | Combinations of beta-lactam compounds, probenecid, and valproic acid and uses thereof | Mar 10, 2021 | Issued |
Array
(
[id] => 17480451
[patent_doc_number] => 20220087955
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => COMBINATION THERAPIES WITH DISULFIRAM
[patent_app_type] => utility
[patent_app_number] => 17/198157
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31865
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17198157
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/198157 | COMBINATION THERAPIES WITH DISULFIRAM | Mar 9, 2021 | Abandoned |
Array
(
[id] => 18938093
[patent_doc_number] => 20240033232
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-01
[patent_title] => New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome
[patent_app_type] => utility
[patent_app_number] => 18/275872
[patent_app_country] => US
[patent_app_date] => 2021-03-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2241
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18275872
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/275872 | New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome | Mar 9, 2021 | Pending |
Array
(
[id] => 17192085
[patent_doc_number] => 11160814
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2021-11-02
[patent_title] => Methods of treatment for disease from coronavirus exposure
[patent_app_type] => utility
[patent_app_number] => 17/194931
[patent_app_country] => US
[patent_app_date] => 2021-03-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19445
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17194931
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/194931 | Methods of treatment for disease from coronavirus exposure | Mar 7, 2021 | Issued |
Array
(
[id] => 17472385
[patent_doc_number] => 20220079889
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-17
[patent_title] => USE OF CANNABANOIDS IN THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY
[patent_app_type] => utility
[patent_app_number] => 17/194087
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26753
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17194087
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/194087 | USE OF CANNABANOIDS IN THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY | Mar 4, 2021 | Abandoned |
Array
(
[id] => 18792600
[patent_doc_number] => 11826333
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Bactericidal debridement compositions for surgical site infections and chronic wound healing
[patent_app_type] => utility
[patent_app_number] => 17/193196
[patent_app_country] => US
[patent_app_date] => 2021-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 12
[patent_no_of_words] => 6182
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17193196
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/193196 | Bactericidal debridement compositions for surgical site infections and chronic wound healing | Mar 4, 2021 | Issued |
Array
(
[id] => 18286734
[patent_doc_number] => 20230102206
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/909302
[patent_app_country] => US
[patent_app_date] => 2021-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17909302
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/909302 | Ibogaine analogs as therapeutics for neurological and psychiatric disorders | Mar 3, 2021 | Issued |
Array
(
[id] => 18389780
[patent_doc_number] => 20230157998
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-25
[patent_title] => Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019
[patent_app_type] => utility
[patent_app_number] => 17/905686
[patent_app_country] => US
[patent_app_date] => 2021-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35958
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17905686
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/905686 | Methods of Inhibiting SARS-CoV-2 Replication and Treating Corona Virus Disease 2019 | Mar 2, 2021 | Pending |
Array
(
[id] => 18509953
[patent_doc_number] => 20230226046
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => IMPROVED TREATMENT OF ATOPIC DERMATITIS WITH TRADIPITANT
[patent_app_type] => utility
[patent_app_number] => 17/760239
[patent_app_country] => US
[patent_app_date] => 2021-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4253
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 132
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17760239
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/760239 | IMPROVED TREATMENT OF ATOPIC DERMATITIS WITH TRADIPITANT | Feb 23, 2021 | Pending |
Array
(
[id] => 16961486
[patent_doc_number] => 20210212985
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-15
[patent_title] => CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS
[patent_app_type] => utility
[patent_app_number] => 17/183319
[patent_app_country] => US
[patent_app_date] => 2021-02-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17183319
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/183319 | CANNABINOIDS FOR PROPHYLACTIC TREATMENT OF INVOLUNTARY WEIGHT LOSS | Feb 22, 2021 | Abandoned |
Array
(
[id] => 17103260
[patent_doc_number] => 11123451
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-21
[patent_title] => Hemostatic devices
[patent_app_type] => utility
[patent_app_number] => 17/178047
[patent_app_country] => US
[patent_app_date] => 2021-02-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 10
[patent_no_of_words] => 7386
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17178047
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/178047 | Hemostatic devices | Feb 16, 2021 | Issued |
Array
(
[id] => 18287061
[patent_doc_number] => 20230102533
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-30
[patent_title] => STARCH PROPIONATE USED AS A FOOD ADDITIVE AND/OR DIETARY SUPPLEMENT FOR PREVENTION OF OVERWEIGHT AND OBESITY
[patent_app_type] => utility
[patent_app_number] => 17/801199
[patent_app_country] => US
[patent_app_date] => 2021-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4309
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17801199
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/801199 | STARCH PROPIONATE USED AS A FOOD ADDITIVE AND/OR DIETARY SUPPLEMENT FOR PREVENTION OF OVERWEIGHT AND OBESITY | Feb 12, 2021 | Pending |
Array
(
[id] => 20356210
[patent_doc_number] => 12472189
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-18
[patent_title] => Treatment and prevention of capillary malformation-arteriovenous malformation
[patent_app_type] => utility
[patent_app_number] => 17/798502
[patent_app_country] => US
[patent_app_date] => 2021-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 43
[patent_figures_cnt] => 47
[patent_no_of_words] => 15182
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17798502
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/798502 | Treatment and prevention of capillary malformation-arteriovenous malformation | Feb 11, 2021 | Issued |